written on 18.03.2014

Why is ThromboGenics' strategic review urgent? Just look at recent Jetrea sales


ThromboGenics admitted last month that slow U.S. sales of its lead drug had put it into a quandary. What could it do to turn the tide? Explore strategic options. Now, the company says sales lagged further for the second half of 2013.